GYRE EBITDA Growth
Gyre Therapeutics Inc · EBITDA Growth
GYRE EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-233.46%period ending
GYRE TTM EBITDA YoY % (-165487.16% → -233.46%)
Year-over-year change
High-resolution chart · PNG
GYRE ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -233.4568% | |
| -105.2442% | |
| -47.9455% | |
| -28.4627% | |
| -63.2059% | |
| -33.7217% | |
| 28.2774% | |
| -17.9487% | |
| 151.8758% | |
| 1,673.6855% | |
| 184.4873% | |
| 154.6836% | |
| 115.5438% | |
| 97.9639% | |
| 74.0145% | |
| 51.797% | |
| 15.0383% | |
| -7.0933% | |
| -56.0032% | |
| -69.5838% | |
| -62.5213% | |
| -69.3092% | |
| -2.066% | |
| 4.1769% | |
| 2.5422% | |
| -4.6448% | |
| -63.4142% | |
| -90.8771% | |
| -92.2755% | |
| -74.0402% | |
| -55.5591% | |
| -42.3018% | |
| -37.9408% | |
| -40.5921% | |
| -23.4476% | |
| -6.0943% | |
| -7.3615% | |
| -18.23% | |
| -34.2905% | |
| -41.485% | |
| -53.3417% | |
| -30.3163% | |
| 33.6568% | |
| 54.2182% | |
| 71.8487% | |
| 77.8815% | |
| 57.906% | |
| 43.5701% | |
| 11.9476% | |
| -281.3379% | |
| -1,265.7126% | |
| -1,248.6216% | |
| -2,002.4081% | |
| 30.5949% | |
| 60.8507% | |
| 7,937.5% | |
| -81.1889% | |
| -196.3116% | |
| -157.8745% | |
| 99.4591% | |
| 197.6107% | |
| 174.2163% | |
| 139.2621% | |
| 72.7506% | |
| 99.8428% | |
| 99.8293% | |
| 99.8276% | |
| 99.9248% | |
| 83.5195% | |
| 69.6004% | |
| 50.07% | |
| -10.4904% | |
| -13.2404% | |
| -27.8976% | |
| 7.3431% | |
| -140.0976% | |
| -228.0927% | |
| -396.9543% | |
| -165,487.1625% |